Latest Breaking News On - Norman sussman - Page 1 : comparemela.com

DURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call Transcript

DURECT Corporation beats earnings expectations. Reported EPS is $-0.27, expectations were $-0.36.

DURECT Corp (DRRX) Reports Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

Topline data anticipated in Q4 2023 CUPERTINO, Calif., June 7, 2023 /PRNewswire/ DURECT Corporation , a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ. | June 7, 2023

DURECT Corporation (NASDAQ:DRRX) Q1 2023 Earnings Call Transcript

Operator: Greetings and welcome to the DURECT Corporation First Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.

DURECT Corporation (NASDAQ:DRRX) Q4 2022 Earnings Call Transcript

Operator: Greetings, and welcome to the DURECT Corporation Fourth Quarter 2022 Earnings Call. . I will now turn the conference over to our host, Tim Papp, Chief Financial Officer. Thank you.